
Anders Jorsal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3338628/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of liraglutide, a glucagonâ€like peptideâ€1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (<scp>LIVE</scp>)—a multicentre, doubleâ€blind, randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 69-77.	7.1	343
2	Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes Care, 2011, 34, 442-447.	8.6	202
3	Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney International, 2008, 74, 649-654.	5.2	124
4	Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2008, 31, 747-752.	8.6	121
5	Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes, 2010, 59, 2027-2032.	0.6	109
6	Plasma Connective Tissue Growth Factor Is an Independent Predictor of End-Stage Renal Disease and Mortality in Type 1 Diabetic Nephropathy. Diabetes Care, 2008, 31, 1177-1182.	8.6	99
7	Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy. Diabetes Care, 2010, 33, 1567-1572.	8.6	98
8	A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes. PLoS Genetics, 2010, 6, e1000842.	3.5	81
9	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2019, 42, 1512-1520.	8.6	77
10	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study. Diabetes, 2017, 66, 2278-2283.	0.6	63
11	Effect of long-term remote ischemic conditioning in patients with chronic ischemic heart failure. Basic Research in Cardiology, 2017, 112, 67.	5.9	45
12	The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes. Molecular Genetics and Metabolism, 2009, 97, 80-84.	1.1	37
13	IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3032-3040.	3.6	32
14	Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. Journal of Nuclear Cardiology, 2018, 25, 169-176.	2.1	32
15	Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets, 2010, 21, 525-532.	2.3	30
16	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. Kidney International, 2017, 92, 1242-1248.	5.2	24
17	A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) Tj ETQq1	10.71894314	rg₿₮ /Overlo
18	Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of Nuclear Cardiology, 2019, 26, 585-597.	2.1	18

ANDERS JORSAL

#	Article	IF	CITATIONS
19	Heart Failure. Endocrinology and Metabolism Clinics of North America, 2018, 47, 117-135.	3.2	17
20	Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 604-608.	2.3	16
21	The impact of the glucagonâ€like peptideâ€1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2141-2150.	4.4	16
22	Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. Nephrology Dialysis Transplantation, 2007, 22, 3235-3239.	0.7	15
23	Optimizing heart failure treatment following cardiac resynchronization therapy. Clinical Research in Cardiology, 2020, 109, 638-645.	3.3	12
24	Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. European Heart Journal, 2020, 41, 328-328.	2.2	12
25	Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. Nephrology Dialysis Transplantation, 2009, 24, 3343-3349.	0.7	11
26	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	1.2	10
27	Quantitative estimation of extravascular lung water volume and preload by dynamic 15O-water positron emission tomography. European Heart Journal Cardiovascular Imaging, 2019, 20, 1120-1128.	1.2	9
28	Visitâ€ŧoâ€visit variability of clinical risk markers in relation to longâ€ŧerm complications in type 1 diabetes. Diabetic Medicine, 2021, 38, e14459.	2.3	7
29	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1603-1608.	2.3	6